Urinary albumin-to-creatinine ratio values are often used to guide treatment decisions as albuminuria is known to be a strong predictor of cardiovascular and renal events.
A move toward combination therapies is inevitable in the new paradigm for diabetic kidney disease management, according to the authors of an editorial.
The effects of combined verinurad and febuxostat treatment were independent of blood pressure.
Improvements seen in glycemic, blood pressure, lipid control within the population partly explain decrease in albuminuria
The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.
Canagliflozin slows progression of kidney disease in participants with eGFR <30 mL/min/1.73 m2 with no increase in AKI
Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.
Whether successful treatment of depression reduces the risk for progression needs to be determined.
The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.
The new KDIGO guideline highlights specific management differences by CKD severity.